Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Abemaciclib Monotherapy Does Not Elicit Responses in Advanced Renal Cell Carcinoma

July 12th 2024

Treatment with single-agent abemaciclib (Verzenio) did not demonstrate clinically meaningful activity in heavily treated patients with metastatic clear cell renal cell carcinoma.

Fianlimab Plus Cemiplimab Yields Early Efficacy Signs in Pretreated Advanced ccRCC

July 12th 2024

Fianlimab plus cemiplimab produced durable responses in heavily pretreated advanced clear cell renal cell carcinoma.

Belzutifan Shows Manageable, Pooled Safety Profile in Advanced VHL-Associated RCC

July 12th 2024

Most patients included in the post-hoc pooled analysis who were treated with belzutifan experienced an all-cause adverse effect.

Dr Semaan on Liquid Biopsy Epigenomic Profiling for the Detection of Sarcomatoid RCC

July 12th 2024

Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.

Dr McGregor on the Data for Abemaciclib in Advanced ccRCC

July 12th 2024

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.

Ongoing Research Aims to Identify Treatment Approaches for Non–Clear Cell RCC Subtypes

July 12th 2024

Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.

No OS Difference Observed After Various Immunotherapy/TKI Regimens in Advanced RCC

July 12th 2024

Real-world treatment patterns demonstrated that similar OS outcomes occurred for patients with renal cell carcinoma who received TKI- and immunotherapy-based regimens.

Dr Choueiri on the Phase 3 TiNivo-2 Study in Pretreated Advanced RCC

July 11th 2024

Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.

Dr Shah on Remaining Unmet Needs in RCC After Frontline IO Combinations

July 11th 2024

Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.

Dr Pal on the Preliminary Efficacy of DFF332 in Advanced ccRCC

July 11th 2024

Sumanta Kumar Pal, MD, FASCO, discusses preliminary findings from a phase 1 dose-escalation study of DFF332 in patients with advanced ccRCC.

Multimodal AI Approach May Help Identify Key Elements to Predict Outcomes in RCC

July 11th 2024

Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.

Nivolumab Plus Ipilimumab Yields Long-Term Efficacy Advantage in Advanced RCC

July 11th 2024

Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.

ADI-270 Earns FDA Fast Track Designation for Pretreated Advanced ccRCC

July 8th 2024

The FDA has granted fast track designation to ADI-270 for advanced clear cell renal cell carcinoma after an immune checkpoint inhibitor and VEGF inhibitor.

Dr Subbiah on the Combination of Sapanisertib and Ziv-Aflibercept in Solid Tumors

July 3rd 2024

Vivek Subbiah, MD, discusses the rationale for combining sapanisertib with ziv-aflibercept in recurrent metastatic solid tumors, including kidney cancer.

Early Data With DFF332, Other Key Biomarker Analyses Continue to Inform Approaches in RCC

July 3rd 2024

Sumanta Kumar Pal, MD, FASCO, highlights key renal cell carcinoma research presented at the 2024 ASCO Annual Meeting, including early data with DFF332.

Dual mTORC1/mTORC2 Inhibitor Sapanisertib Shows Promise in Combination Regimens for Solid Tumors

July 2nd 2024

Vivek Subbiah, MD, details the rationale for combining sapanisertib with ziv-aflibercept or metformin and next steps for mTOR inhibitors in solid tumors.

Dr Bilusic on the Investigation of Enfortumab Vedotin in Rare GU Cancers

June 26th 2024

Marijo Bilusic, MD, PhD, discusses the investigation of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors.

Dr Linscott on Urinary Cell-free Tumor DNA to Predict MRD in High-risk NMIBC

June 25th 2024

Joshua Linscott, MD, discusses using urinary cell-free tumor DNA to predict minimal residual disease in high-risk non-muscle invasive bladder cancer.

EMA Validates Filings for Subcutaneous Formulation of Nivolumab in Solid Tumors

June 21st 2024

The EMA has validated an extension application for the subcutaneous formulation of nivolumab in adult patients with solid tumor indications.

Dr Grivas on Key Updates in Genitourinary Cancer Management

June 17th 2024

Petros Grivas, MD, PhD, and Chandler H. Park, MD, FACP, discuss key updates in genitourinary cancer on OncLive News Network: On Location.